|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Osaki M, Takeshita F, Sugimoto Y, et al:
MicroRNA-143 regulates human osteosarcoma metastasis by regulating
matrix metalloprotease-13 expression. Mol Ther. 19:1123–1130. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Federman N, Bernthal N, Eilber FC and Tap
WD: The multidisciplinary management of osteosarcoma. Curr Treat
Option Oncol. 10:82–93. 2009. View Article : Google Scholar
|
|
4
|
Salah S, Ahmad R, Sultan I, et al:
Osteosarcoma with metastasis at initial diagnosis: Current outcomes
and prognostic factors in the context of a comprehensive cancer
center. Mol Clin Oncol. 2:811–816. 2014.PubMed/NCBI
|
|
5
|
Qu JT, Wang M, He HL, Tang Y and Ye XJ:
The prognostic value of elevated vascular endothelial growth factor
in patients with osteosarcoma: a meta-analysis and systemic review.
J Cancer Res Clin Oncol. 138:819–825. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nagarajan R, Kamruzzaman A, Ness KK, et
al: Twenty years of follow-up of survivors of childhood
osteosarcoma: a report from the Childhood Cancer Survivor Study.
Cancer. 117:625–634. 2011. View Article : Google Scholar :
|
|
7
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: state of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jia L, Ma S, Hou X, et al: The synergistic
effects of traditional Chinese herbs and radiotherapy for cancer
treatment. Oncol Lett. 5:1439–1447. 2013.PubMed/NCBI
|
|
9
|
Shi RX, Ong CN and Shen HM: Luteolin
sensitizes tumor necrosis factor-α-induced apoptosis in human tumor
cells. Oncogene. 23:7712–7721. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin SY, Liu JD, Chang HC, et al: Magnolol
suppresses proliferation of cultured human colon and liver cancer
cells by inhibiting DNA synthesis and activating apoptosis. J Cell
Biochem. 84:532–544. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chiou WF, Chou CJ, Shum AY and Chen CF:
The vasorelaxant effect of evodiamine in rat isolated mesenteric
arteries: mode of action. Eur J Pharmacol. 215:277–283. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choi YH, Shin EM, Kim YS, Cai XF, Lee JJ
and Kim HP: Anti-inflammatory principles from the fruits of Evodia
rutaecarpa and their cellular action mechanisms. Arch Pharm Res.
29:293–297. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kobayashi Y: The nociceptive and
anti-nociceptive effects of evodiamine from fruits of Evodia
rutaecarpa in mice. Planta Med. 69:425–428. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fei XF, Wang BX, Li TJ, et al: Evodiamine,
a constituent of Evodiae Fructus, induces anti-proliferating
effects in tumor cells. Cancer Sci. 94:92–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Wu LJ, Tashiro S, Onodera S and
Ikejima T: Evodiamine induces tumor cell death through different
pathways: apoptosis and necrosis. Acta Pharmacol Sin. 25:83–89.
2004.PubMed/NCBI
|
|
16
|
Kan SF, Yu CH, Pu HF, Hsu JM, Chen MJ and
Wang PS: Anti-proliferative effects of evodiamine on human prostate
cancer cell lines DU145 and PC3. J Cell Biochem. 101:44–56. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kan SF, Huang WJ, Lin LC and Wang PS:
Inhibitory effects of evodiamine on the growth of human prostate
cancer cell line LNCaP. Int J Cancer. 110:641–651. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liao CH, Pan SL, Guh JH, et al: Antitumor
mechanism of evodiamine, a constituent from Chinese herb Evodiae
fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES
cells in vitro and in vivo. Carcinogenesis. 26:968–975. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Wu LJ, Tashiro S, Onodera S and
Ikejima T: Evodiamine induces A375-S2 cell death through two
different pathways. Yao Xue Xue Bao. 38:650–653. 2003.(In
Chinese).
|
|
20
|
Huang YC, Guh JH and Teng CM: Induction of
mitotic arrest and apoptosis by evodiamine in human leukemic
T-lymphocytes. Life Sci. 75:35–49. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hockenbery DM, Oltvai ZN, Yin XM, et al:
Bcl-2 functions in an antioxidant pathway to prevent apoptosis.
Cell. 75:241–251. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Antonsson B: Bax and other pro-apoptotic
Bcl-2 family “killer-proteins” and their victim the mitochondrion.
Cell Tissue Res. 306:347–361. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jiang J and Hu C: Evodiamine: a novel
anti-cancer alkaloid from Evodia rutaecarpa. Molecules.
14:1852–1859. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brunelle JK and Letai A: Control of
mitochondrial apoptosis by the Bcl-2 family. J Cell Sci.
122:437–441. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fiandalo MV and Kyprianou N: Caspase
control: protagonists of cancer cell apoptosis. Exp Oncol.
34:165–175. 2012.PubMed/NCBI
|
|
26
|
Yang J, Liu X, Bhalla K, et al: Prevention
of apoptosis by Bcl-2: release of cytochrome c from mitochondria
blocked. Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Siu WP, Pun PB, Latchoumycandane C and
Boelsterli UA: Bax-mediated mitochondrial outer membrane
permeabilization (MOMP), distinct from the mitochondrial
permeability transition, is a key mechanism in diclofenac-induced
hepatocyte injury: Multiple protective roles of cyclosporin A.
Toxicol Appl Pharmacol. 227:451–461. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ohtsuka T, Buchsbaum D, Oliver P, Makhija
S, Kimberly R and Zhou T: Synergistic induction of tumor cell
apoptosis by death receptor antibody and chemotherapy agent through
JNK/p38 and mitochondrial death pathway. Oncogene. 22:2034–2044.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Swanton E, Savory P, Cosulich S, et al:
Bcl-2 regulates a caspase-3/caspase-2 apoptotic cascade in
cytosolic extracts. Oncogene. 18:1781–1787. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Park JW, Choi YJ, Suh SI, et al: Bcl-2
overexpression attenuates resveratrol-induced apoptosis in U937
cells by inhibition of caspase-3 activity. Carcinogenesis.
22:1633–1639. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Osaka E, Suzuki T, Osaka S, et al:
Survivin expression levels as independent predictors of survival
for osteosarcoma patients. J Orthop Res. 25:116–121. 2007.
View Article : Google Scholar
|
|
32
|
Altieri DC: Survivin, versatile modulation
of cell division and apoptosis in cancer. Oncogene. 22:8581–8589.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu CD, Altieri DC and Tanigawa N:
Expression of a novel antiapoptosis gene, survivin, correlated with
tumor cell apoptosis and p53 accumulation in gastric carcinomas.
Cancer Res. 58:1808–1812. 1998.PubMed/NCBI
|
|
34
|
Tanaka K, Iwamoto S, Gon G, Nohara T,
Iwamoto M and Tanigawa N: Expression of survivin and its
relationship to loss of apoptosis in breast carcinomas. Clin Cancer
Res. 6:127–134. 2000.PubMed/NCBI
|
|
35
|
Kawasaki H, Altieri DC, Lu CD, Toyoda M,
Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin
predicts shorter survival rates in colorectal cancer. Cancer Res.
58:5071–5074. 1998.PubMed/NCBI
|
|
36
|
Tamm I, Wang Y, Sausville E, et al:
IAP-family protein survivin inhibits caspase activity and apoptosis
induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer
Res. 58:5315–5320. 1998.PubMed/NCBI
|
|
37
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar
|
|
38
|
Suzuki A and Shiraki K: Tumor cell ‘dead
or alive’: caspase and survivin regulate cell death, cell cycle and
cell survival. Histol Histopathol. 16:583–593. 2001.PubMed/NCBI
|
